@article{3099164,
    title = "Switching to amisulpride monotherapy for treatment-resistant
schizophrenia",
    author = "Kontaxakis, VP and Havaki-Kontaxaki, BJ and Ferentinos, PP and Paplos, and KG and Soldatos, CR",
    journal = "European Psychiatry",
    year = "2006",
    volume = "21",
    number = "3",
    pages = "214-217",
    publisher = "ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER",
    issn = "0924-9338",
    doi = "10.1016/j.eurpsy.2006.01.013",
    keywords = "schizophrenia; antipsychotics; treatment resistance; amisulpride",
    abstract = "The objective of this study was to assess switching to amisulpride (AMS)
in treatment-resistant schizophrenia. Seven mate subjects were switched
to AMS and followed for 8 weeks. PANSS scores improved from 123 to 66
over this period. We conclude that AMS is of interest in the treatment
of refractory schizophrenia. (c) 2006 Elsevier SAS. All rights reserved."
}